Peter Mullen

School of Medicine, University of St Andrews

Research Area

Biography

Peter Mullen has not added Biography.
If you are Peter Mullen and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title Cited by 12	2013

Other Publications

Article	Year
PARP cleavage as a means of assessing apoptosis. Methods in molecular medicine\| PubMed ID: 14634228	2004
Flow cytometric DNA analysis of human cancer cell lines. Methods in molecular medicine\| PubMed ID: 14634236	2004
The use of Matrigel to facilitate the establishment of human cancer cell lines as xenografts. Methods in molecular medicine\| PubMed ID: 14634240	2004
Antisense oligonucleotide targeting of Raf-1: importance of raf-1 mRNA expression levels and raf-1-dependent signaling in determining growth response in ovarian cancer. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 15041731	2004
Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer. Cancer research\| PubMed ID: 16061661	2005
Comparison of strategies targeting Raf-1 mRNA in ovarian cancer. International journal of cancer. Journal international du cancer\| PubMed ID: 16184551	2006
Raf-1 is the predominant Raf isoform that mediates growth factor-stimulated growth in ovarian cancer cells. Carcinogenesis\| PubMed ID: 16332724	2006
Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling. Molecular cancer therapeutics\| PubMed ID: 17237269	2007
Gonadotropin-releasing hormone receptor levels and cell context affect tumor cell responses to agonist in vitro and in vivo. Cancer research\| PubMed ID: 18676858	2008
Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab. Cancer research\| PubMed ID: 19638581	2009
Modulation of HER3 is a marker of dynamic cell signaling in ovarian cancer: implications for pertuzumab sensitivity. Molecular cancer research : MCR\| PubMed ID: 19737968	2009
Effect of simvastatin on cholesterol metabolism in C2C12 myotubes and HepG2 cells, and consequences for statin-induced myopathy. Biochemical pharmacology\| PubMed ID: 20018177	2010
Serotonin, a catecholamine? Headache\| PubMed ID: 20100295	2010
Pertuzumab for the treatment of ovarian cancer. Expert opinion on biological therapy\| PubMed ID: 20465533	2010
Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells. Cancer research\| PubMed ID: 20861192	2010
Phosphoprotein pathway profiling of ovarian carcinoma for the identification of potential new targets for therapy. European journal of cancer (Oxford, England : 1990)\| PubMed ID: 21334202	2011
Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 21571868	2011
Susceptibility to simvastatin-induced toxicity is partly determined by mitochondrial respiration and phosphorylation state of Akt. Biochimica et biophysica acta\| PubMed ID: 21839782	2011
Sprouty 2 is an independent prognostic factor in breast cancer and may be useful in stratifying patients for trastuzumab therapy. PloS one\| PubMed ID: 21909357	2011
Features of the reversible sensitivity-resistance transition in PI3K/PTEN/AKT signalling network after HER2 inhibition. Cellular signalling\| PubMed ID: 21996585	2012
Model-based global sensitivity analysis as applied to identification of anti-cancer drug targets and biomarkers of drug resistance in the ErbB2/3 network. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences\| PubMed ID: 22085636	2011
Diversity of matriptase expression level and function in breast cancer. PloS one\| PubMed ID: 22514623	2012
Ureido-substituted sulfamates show potent carbonic anhydrase IX inhibitory and antiproliferative activities against breast cancer cell lines. Bioorganic & medicinal chemistry letters\| PubMed ID: 22721713	2012
Effect of short- and long-term treatment with valproate on carnitine homeostasis in humans. Therapeutic drug monitoring\| PubMed ID: 22743351	2012
New strategies for targeting the hypoxic tumour microenvironment in breast cancer. Cancer treatment reviews\| PubMed ID: 23063837	2013